Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs UnitedHealth Group Inc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while UnitedHealth Group Inc trades at $398.07 (market cap $339.08B). The key difference: UnitedHealth Group Inc is far larger — about 348.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and UnitedHealth Group Inc pays a 2.46% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and UnitedHealth Group Inc for 98 Days on average.
| MRVI | UNH | |
|---|---|---|
Market Cap | $972.90M | $339.08B |
Volume | 4,325,710 | 12,648,635 |
Sector | Health | Health |
52-Week High | $9.00 | $436.35 |
52-Week Low | $2.83 | $259.02 |
Typical Hold Time | 0 Days | 98 Days |
Enterprise Value | $1.08B | $380.94B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
UnitedHealth Group (UNH) trades at $377.76, down 0.2% on the day, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $6.38 surpassing the $4.91 expectation. Revenue reached $447.57 billion in 2025, though net income margin declined to 2.69%. Recent news highlights dividend payments and strategic moves like the TPG deal for WellMed clinics.
UNH presents a favorable outlook with a consensus price target of $470.11, implying significant upside. Strengths include robust cash flow, a dominant market position, and AI investments in Optum. Risks involve regulatory pressures, rising medical costs, and debt levels. The stock remains a core holding for growth-oriented investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
